Manual of Pediatric Hematology and Oncology

Manual of Pediatric Hematology and Oncology

Volumn , Issue , 2005, Pages

  Lanzkowsky, Philip ^a,b  

^a Hofstra Northwell Steven and Alexandra Cohen Children s Medical Center of NY Northwell Health   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013964500     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-088524-4.X5000-6     Document Type: Book

References (454)

1. Bessman JD, Gilmer PR, Gardner FH Improved classification of anemias by MCV and RDW. Am J Clin Pathol 1983, 80:322.
2. Blanchette V, Zipursky A Assessment of anemia in newborn infants. Clin Perinatol 1984, 11:489.
3. Lanzkowsky P Diagnosis of anemia in the neonatal period and during childhood. Pediatric Hematology-Oncology: A Treatise for the Clinician 1980, 3. McGraw-Hill, New York.
4. Academy of Pediatrics Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia. Pediatrics 1994, 94:558-565.
5. Bowman J The management of hemolytic disease in the fetus and newborn. Semin Perinatol 1997, 21:39-44.
6. Halperin DS, Wacker P, LaCourt G, et al. Effects of recombinant human erythropoietin in infants with the anemia of prematurity: a pilot study. J Pediatr 1990, 116:779-796.
7. Hann IM, Gibson BES, Letsky EA Fetal and Neonatal Haematology 1991, Bailliere Tindall, London.
8. Maier RH, Obladen M, Müller-Hansen I, et al. Early treatment with erythropoietin [beta] ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr 2002, 141:8-15.
9. Messer J, Haddad J, Donato L, Astruc D, et al. Early treatment of premature infants with recombinant human erythropoietin. Pediatrics 1993, 92:519-523.
10. Ballin A, Berar M, Rubinstein U, et al. Iron state in female adolescents. Am J Dis Child 1992, 146:803-805.
11. Committee on Nutrition Iron supplementation for infants. Pediatrics 1976, 58:765-768.
12. Dallman PR Iron deficiency and related nutritional anemias. Hematology of Infancy and Childhood 1987, WB Saunders, Philadelphia. D.G. Nathan, F.A. Oski (Eds.).
13. Dallman PR Progress in the prevention of iron deficiency in infants. Acta Paediatr Scan 1990, 365(Suppl):28-37.
14. Dallman PR, Reeves JD Laboratory diagnosis of iron deficiency. Iron Nutrition in Infancy and Childhood 1984, 11. Raven Press, New York. A. Steckel (Ed.).
15. Lanzkowsky P Iron deficiency anemias: A systemic disease. Trans College Medicine South Africa July-December 1982, 67-113.
16. Lanzkowsky P Iron-deficiency anemia. Pediatric Hematology-Oncology: A Treatise for the Clinician 1980, McGraw-Hill, New York.
17. Lanzkowsky P Iron metabolism and iron deficiency anemia. Blood Diseases of Infancy and Childhood 1978, CV Mosby, St. Louis. 4th ed. D.R. Miller, M.A. Pearson, R.L. Baehner, C.W. McMillan (Eds.).
18. Lukens JN Iron metabolism and iron deficiency anemia. Blood Diseases of Infancy and Childhood 1984, CV Mosby, St. Louis. D.R. Miller, R.L. Baehner, C.W. McMillan (Eds.).
19. Oski FA Iron deficiency in infancy and childhood. N Engl J Med 1993, 329:190-193.
20. Carmel R Bevond megaloblastic anemia: new paradigms of cobalamin and folate deficiency. Semin Hematol 1999, 36(1).
21. Chanarin I Management of megaloblastic anemia in the very young. Brit J Haematol 1983, 53:1-3.
22. Chanarin I The Megaloblastic Anemias 1990, Blackwell Scientific Publications, Oxford. 3rd ed.
23. Cooper BA, Rosenblatt DS, Whitehead VM Megaloblastic anemia. Hematology of Infancy and Childhood 1993, WB Saunders, Philadelphia.
24. Heisel MA, Siegel SE, Falk RE, et al. Congenital pernicious anemia: report of seven patients with studies of the extended family. J Pediatr 1984, 105:564-568.
25. Lanzkowsky P The megaloblastic anemias: folate deficiency II. Clinical, pathogenetic and diagnostic considerations in folate deficiency. Hematology of Infancy and Childhood 1987, WB Saunders, Philadelphia. D.G. Nathan, F.A. Oski (Eds.).
26. 12 (cobalamin) deficiency and other congenital and acquired disorders. Hematology of Infancy and Childhood 1987, WB Saunders, Philadelphia. D.G. Nathan, F.A. Oski (Eds.).
27. Charrow J, Anderson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with Type 1 Gaucher disease: consensus recommendations. J Pediatr 2004, 144:112-120.
28. Eschbach J, Abdulhadi M, et al. Recombinant human erythropoietin in anemic subjects with end-stage renal disease: results of phase III multicenter clinical trial. Am Intern Med 1989, 111:992.
29. Grabowski GA, Leslie N Lysosomal storage diseases: perspectives and principles. Hematology Basic Principles and Practice 2000, Lippincott-Raven, Philadelphia. 3rd ed. R. Hoffmann, E.J. Benz, S.J. Shattil, B. Furie, H.J. Cohen, L.E. Silberstein, P. McGlave (Eds.).
30. Granovsky MO, Mueller BU, Nicholson HS, Rosenberg PS, Rabkin CS Cancer in human immunodeficiency virus-infected children: a case series from the Children's Cancer Group and the National Cancer Institute. J Clin Oncol 1998, 16:1729.
31. Kolodney EH, Charria-Ortiz G Storage diseases of the reticuloendothelial system. Nathan and Oski's Hematology of Infancy and Childhood 2003, WB Saunders, Philadelphia. 6th ed. D. Nathan, S.H. Orkin, D. Ginsburg, A.T. Look (Eds.).
32. McClain KL, Joshi VV Cancer in children with HIV infection. Hematol Oncol Clin North Am 1996, 10:1189.
33. McGovern MM, Desnick RJ Lipidoses. Nelson Textbook of Pediatrics 2004, WB Saunders, Philadelphia. 17th ed. R.E. Behrman, R.M. Kliegman, H.B. Jenson (Eds.).
34. Mueller BU, Pizza PA Cancer in children with primary or secondary immunodeficiencies. J Pediatr 1995, 126:1.
35. Scadden DT Hematologic disorders and growth factor in HIV infection. Hematol Oncol Clin North Am 1996, 10:1149.
36. Sinai-Trieman L, Salusky I, et al. The use of subcutaneous recombinant erythropoietin in children undergoing continuous cycling peritoneal dialysis. J Pediatr 1989, 114:550.
37. Stockman J, Ezekowitz A Hematologic manifestations of systemic diseases. Nathan and Oski's Hematology of Infancy and Childhood 1998, 1841-1891. WB Saunders, Philadelphia. 5th ed. D. Nathan, S. Orkin (Eds.).
38. Alter B Lipton, Fanconi J. Anemia EMedicine J 2002, [serial online], Available at. http://www.emedicine.com/ped/topic3022.htm.
39. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-the European Group for Blood and Marrow Transplantation Experience. Semin Hematol 2000, 37:69-80.
40. Ball SE The modern management of severe aplastic anemia. Br J Haematol 2001, 110:41-53.
41. Bridges KR Sideroblastic anemia: a mitochondrial disorder. J Pediatr Hematol Oncol 1997, 19:274-278.
42. Brodsky RA, Sensenbrenner LL, Jones RJ Complete remission in severe aplastic anemia after high dose cyclophosphamide without bone marrow transplantation. Blood 1996, 87:491-494.
43. Brown KE, Tisdale J, Barnett J, Dunbar CE, Young NS Hepatitis associated aplastic anemia. N Engl J Med 1997, 1059-1064.
44. Camitta B, Thomas ED, Nathan DG, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 1979, 53:504-515.
45. Cherrick I, Karayalcin G, Lanzkowsky P Transient erythroblastopenia of childhood. Am J Pediatr Hematol Oncol 1994, 16:320-324.
46. Connor JM, Gatherer D, Gray FC, Pirrit LA, Affara NA Assignment of the gene for dyskeratosis congenita to Xq28. Human Genet 1986, 72:348-351.
47. De Plauque M, Bacigalupo A, Wursch A, Hows JM, et al. Long term follow-up of severe aplastic anemia patients treated with antithymocytic globulin. Br J Haematol 1989, 73:121-126.
48. Dokal I Dyskeratosis congenita in all its forms (Review). Br J Haematol 2000, 110:768-779.
49. Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig T-N, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anemia. Nat Genet 1999, 21:169-175.
50. Frickhofen N, Kaltwasser JP, Schrezenmeir H, Raghavachar A, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med 1991, 324:1297-1304.
51. Gazda H, Lipton JM, Willig T-N, Ball S, et al. Evidence for linkage of familial Diamond-Blackfan anemia to chromosome 8p23.2-23.1 and non-19q non-8p familial disease. Blood 2001, 97:2145-2150.
52. Grompe M FANCD2: a branch-point in DNA damage response?. Nat Med 2002, 8:555-556.
53. Hedberg VA, Lipton M Thrombocytopenia with absent radii. A review of 100 cases. Am J Pediatr Hematol Oncol 1988, 10:51-64.
54. Hillmen P, Lewis SM, Bressler M, Luzzatto L, Dacie JV Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995, 333:1253-1258.
55. Joenje H, Patel KJ The emerging genetic and molecular basis of Fanconi anemia. Nat Rev Genet 2001, 2:446-457.
56. Kerr DS Protein manifestations of mitochondrial disease: a mini-review. J Pediatr Hematol Oncol 1997, 19:279-286.
57. Koenig JM, Ashton D, DeVore GR, Christensen RD Late hyporegenerative anemia in Rh-hemolytic disease. J Pediatr 1989, 115:315-318.
58. Kojima S, Horibe K, Inaba J, et al. Long term outcome of acquired aplastic anemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol 2000, 11:321-328.
59. Lipton JM, Federman N, Khabbaze, Schwartz CL, et al. Osteogenic sarcoma associated with Diamond-Blackfan anemia: a report from the Diamond-Blackfan Anemia Registry. J Pediatr Hematol Oncol 2001, 23:39-44.
60. Nathan DG, Orkin SH Hematology of Infancy and Childhood 1998, WB Saunders, Philadelphia. 5th ed.
61. Perdahl EB, Naprstek BL, Wallace WC, Lipton JM Erythroid failure in Diamond-Blackfan anemia is characterized by apoptosis. Blood 1994, 83:645-650.
62. Ponka P Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanism in erythroid cells. Blood 1997, 89:1-25.
63. Rosenberg PS, Greene MH, Alter BP Cancer incidence in persons with Fanconi's anemia. Blood 2003, 101:822-826.
64. Shalev H, Tamary H, Shaft D, Reznitsky P, Zaizov R Neonatal manifestations of congenital dysery thropoietic anemia type I. J Pediatr 1997, 131:95-97.
65. Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anemia Working Party. N Engl J Med 1993, 329:1152-1157.
66. Vlachos A, Klein GW, Lipton JM The Diamond-Blackfan Anemia Registry: tool for investigating the epidemiology and biology of Diamond-Blackfan anemia. J Pediatr Hematol Oncol 2001, 23:377-382.
67. Vulliamy T, Marron A, Goldman F, Dearlove A, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001, 413:432-435.
68. Wickramasinghe SN Dyserythropoiesis and congenital dyserythropoietic anemias. Br J Haematol 1997, 98:785-797.
69. Young NS, Alter BP Aplastic Anemia: Acquired and Inherited 1994, WB Saunders, Philadelphia.
70. Becker P, Lux S Disorders of the red cell membrane. Hematology of Infancy and Childhood 1993, WB Saunders, Philadelphia. D. Nathan, F. Oski (Eds.).
71. Dacie J The Haemolytic Anaemias 3. The Auto-Immune Haemolytic Anaemias 1992, Churchill Livingstone, Edinburgh. 3rd ed.
72. Lanzkowsky P Hemolytic anemia. Pediatric Hematology Oncology: A Treatise for the Clinician 1980, McGraw-Hill, New York.
73. Luzzatto L G6PD deficiency and hemolytic anemia. Hematology of Infancy and Childhood 1993, WB Saunders, Philadelphia. D.G. Nathan, F.A. Oski (Eds.).
74. Mentzer W Pyruvate kinase deficiency and disorders of glycolysis. Hematology of Infancy and Childhood 1987, WB Saunders, Philadelphia. D.G. Nathan, F.A. Oski (Eds.).
75. Clinics in Haematology: Enzymopathies 1981, 10. WB Saunders, Philadelphia. W. Mentzer (Ed.).
76. Nathan D, Orkin S Nathan and Oski's Hematology of Infancy and Childhood 1998, 811-817. WB Saunders, Philadelphia. 5th ed.
77. Schreiber A, Gill F Autoimm une hemolytic anemia. Hematology of Infancy and Childhood 1987, WB Saunders, Philadelphia. D.G. Nathan, F.A. Oski (Eds.).
78. Adekile AD, Tuli M, Haider MZ, et al. Influence of α-thalassemia trait on spleen function in sickle cell anemia patients with high HbF. Am J Hematol 1996, 36:184-189.
79. Bernaudin F, Soullet G, Vannier JP, et al. Bone marrow transplantation in 14 children with severe sickle cell disease: the French experience. GEGMO Bone Marrow Transplantation 1993, 12:118.
80. Bounga JC, Mouélé R, Préhu C, et al. Glucose-6-phosphate dehydrogenase deficiency and homozygous sickle cell disease in Congo. Hum Hered 1998, 48:192-197.
81. Driscoll MC, Hurlet A, Berman B, et al. Stroke risk in sibling pairs with sickle cell disease. Am J Hum Genet 1999, 65:A201.
82. Ferrone F, Nagel RL Polymer structure and poly merization of deoxyhemoglobin S. Disorders of Hemoglobin: Genetics, Pathophysiology, Clinical Management 2001, Cambridge University Press, Cambridge, UK. M.H. Steinberg, B.G. Forget, D.R. Higgs (Eds.).
83. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: pediatric clinical trial. Blood 1996, 88:1960.
84. Garner C, Tatu T, Reittie JE, et al. Genetic influences on F cells and other hematologic variables: a twin heritability study. Blood 2000, 95:342-346.
85. Gore L, Lane P, Quinones RR, Giller RH Successful cord blood stem cell transplantation for sickle cell anemia from an HLA-identical sibling. Blood 1997, 90:388b.
86. Nagel RL Severity, pathobiology, epistatic effects, and genetic markers in sickle cell anemia. Semin Hematol 1991, 28:180-201.
87. Noguchi CT, Rodgers GP, Serjeant G, et al. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 1988, 318:96-99.
88. s-gene-cluster haplotypes as prognostic indicators of vital organ failure. Semin Hematol 1991, 28:202-208.
89. s-gene-cluster haplotypes in sickle cell anemia. Clinical and hematologic features. Hematol Oncol Clin North Am 1991, 5:475-493.
90. Rogers Z Hydroxyurea therapy for diverse pediatric population with sickle cell disease. Semin Hematol 1997, 34:42.
91. Steinberg MH Compound heterozygous and other sickle hemoglobinopathies. Disorders of Hemoglobin: Genetics, Pathophysiology, Clinical Management 2001, Cambridge University Press, Cambridge, UK. M.H. Steinberg, B.G. Forget, D.R. Higgs (Eds.).
92. Vermylen C, Cornu G Hematopoietic stem cell transplant for sickle cell anemia. Curr Opin Hematol 1997, 4:377.
93. Weiss M, Blobel G Nuclear factors that regulate erythropoiesis. Disorders of Hemoglobin: Genetics, Pathophysiology, Clinical Management 2001, Cambridge Universit Press, Cambridge, UK. M.H. Steinberg, B.G. Forget, D.R. Higgs (Eds.).
94. Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet 2002, 360:516-520.
95. *) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001, 22:2171-2179.
96. Angelucci E, Brittenham GM, McLaren C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000, 343:327-331.
97. Chui DHK, Fucharoen S, Chan V Hemoglobin H disease: not necessarily a benign disorder. Blood 2003, 101:791-800.
98. Cohen A Cooley's anemia seventh symposium. Ann NY Acad Sci 1998, 850.
99. Cunningham M, Macklin E, Neufeld E, Cohen A Complications of β-thalassemia major in North America. Blood 2004, 104:34-39.
100. Lawson SE, Roberts IA, Amrolia P, Dokal I, Szydlo R, Darbyshire PJ Bone marrow transplantation for beta-thalassaemia major: the UK experience in two paediatric centres. Br J Haematol 2003, 120(2):289-295.
101. Lowrey C, Nienhuis A Brief report: treatment with azacytidine of patients with end-stage beta-thalassemia. N Engl J Med 1993, 329(12):845-848.
102. Lucarelli G, Galimberti M, Pochi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993, 29:840-844.
103. Olivieri N The β-thalassemias. N Engl J Med 1999, 341(2):99-109.
104. Orkin SH, Nathan DG The Thalassemias. Hematology of Infancy and Childhood 2003, WB Saunders, Philadelphia. 6th ed. D. Nathan, F. Oski (Eds.).
105. Cazzola M, Guarnone R, et al. Congenital erythropoietin-dependent erythrocytosis responsive to theophylline treatment. Blood 1998, 91:360.
106. Ebert BL, Bunn HF Regulation of the erythropoietin gene. Blood 1999, 94:1864.
107. Fisher JW Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003, 228:1-14.
108. Gilbert HS Modern treatment strategies in polycythemia vera. Semin Hematol 2003, 40:26-29.
109. Hermansen MC Nucleated red blood cells in the fetus and newborn. Arch Dis Child Fetal Neonatal Ed 2001, 84:F211-F215.
110. Linndemann R, Haga P Evaluation and treatment of polycythemia in the neonate. Hematologic Problems of the Neonate 2000, WB Saunders, Philadelphia. R.D. Christensen (Ed.).
111. Prchal JT Classification and molecular biology of polycythemias (erythrycytoses) and thrombocytosis. Hematol Oncol Clin North Am 2003, 17:1151-1158.
112. Prachal JT, Sokol L Benign erythrocytosis and other familial and congenital polycythemias. Eur J Haematol 1996, 57:263-268.
113. Sergeyeva A, Gordeuk VR, et al. Congenital polycythemia in Chuvashia. Blood 1997, 89:2148.
114. Vlahakos DV, et al. Posttransplant erythrocytosis. Kidney Int 2003, 63:1187-1194.
115. Werner EJ Neonatal polycythemia and hyperviscosity. Clin Perinatol 1995, 22:693.
116. Bernini JC Diagnosis and management of chronic neutropenia during childhood. Pediatr Clin North Am 1996, 43:773-786.
117. Brito-Babapulle F The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 2003, 121:203-223.
118. Bux J, Mueller-Eckhardt C Autoimmune neutropenia. Semin Hematol 1992, 29:45-53.
119. Boxer L, Dale DC Neutropenia: causes and consequences. Semin Hematol 2002, 39:75-81.
120. Carr R Neutrophil production and function in newborn infants. Br J Haematol 2000, 110:18-28.
121. Cartron J, Tchernia G, Cleton J, Damay M, Cheron G, Farrokhi P, Badoual J Alloim mune neonatal neutropenia. Am J Pediatr Hematol Oncol 1991, 13:21-25.
122. Cottle TE, Fier CJ, Donadieu J, Kinsey SE Risk and benefit of treatment of severe neutropenia with granulocyte colony-stimulating factors. Semin Hematol 2002, 39:134-140.
123. Severe Chronic Neutropenia, Seminars in Hematology 2002, 29. WB Saunders, Philadelphia. D.C. Dale (Ed.).
124. Severe Chronic Neutropenia, Seminars in Hematology 2002, 73-133. WB Saunders, Philadelphia. D.C. Dale (Ed.).
125. Dinauer MC The phagocyte system and disorders of granulopoiesis and granulocyte function. Hematology of Infancy and Childhood 2003, WB Saunders, Philadelphia. 6th ed. D.G. Nathan, S.H. Orkin, D. Ginsburg, A.T. Look (Eds.).
126. Horwitz M, Li F, et al. Leukemia in severe congenital neutropenia: Defective proteolysis suggests new pathways to malignancy and opportunities for therapy. Cancer Investigation 2003, 21:579-587.
127. Josson OG, Buchanan GR Chronic neutropenia during childhood: A 13-year experience in a single institution. Am J Dis Child 1991, 145:232-235.
128. Karlsson S Treatment of genetic defects in hematopoietic cell function by gene transfer. Blood 1991, 78:2481-2492.
129. Klion AO, Robyn J, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004, 103:473-476.
130. Lalezari P, Khorshidi M, Petrosova M Autoimmune neutropenia of infancy. J Pediatr 1986, 109:764.
131. Shastri KA, Logue GL Autoimmune neutropenia. Blood 1993, 81:1984-1995.
132. Sulliva JL Hematologic consequences of Epstein-Barr virus infection. Hematol Oncol Clin North Am 1987, 1:397.
133. Vlachos A, Lipton JM Hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. Pediatric Stem Cell Transplantation 2004, Jones and Bartlett Publishers, Boston. P. Mehta (Ed.).
134. Yang K, Hill H Neutrophill function disorders: pathophysiology, prevention, and therapy. J Pediatr 1991, 119:343-354.
135. Bianch V, Robles R, Alberio L, et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002, 100:710-713.
136. Blanchette VS, Price V Childhood chronic immune thrombocytopenic purpura: unresolved issues. J Pediatr Hematol Oncol 2003, 25:S28-S33.
137. Bolton-Maggs PHB Idiopathic thrombocytopenic purpura. Arch Dis Child 2000, 83:220-222.
138. Bussell JB, Skupski DW, MacFarland JG Fetal alloimmune thrombocytopenia: concensus and controversy. The Journal of Maternal-Fetal Medicine 1996, 5:281-292.
139. Cines DB, Blanchette VS Medical progress: immune thrombocytopenic purpura. New Engl J Med 2002, 346(13):995-1008.
140. Fetal alloimmune thrombocytopenia: consensus and controversy. J Maternal-Fetal Med 1996, 5:281-292.
141. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by the explicit methods for the American Society of Hematology. Blood 1996, 88(1):3-40.
142. Heath KE, Campos-Barros A, Toren A, et al. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant thrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein and Alport-like syndromes. Am J Hum Genet 2001, 69:1033-1045.
143. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant thrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 2001, 69:1033-1045.
144. Vesely SK, George JN, Lammie B, et al. ADAMTS13 activity in thrombotic thrombo-cytopenic purpura-hemolytic uremic syndrome; relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003, 102(1):60-68.
145. Wilson DB Acquired platelet defects. Nathan and Oski's hematology of Infancy and Childhood 2003, W.B. Saunders, Philadelphia. 6th ed. D.G. Nathan, S.H. Orkin, D. Ginsburg, A.T. Look (Eds.).
146. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L Maturation of the hemostatic system during childhood. Blood 1992, 80:1998-2005.
147. Bick R Disseminated intravascular coagulation: objective criteria for clinical and laboratory diagnosis and assessment of therapeutic response. Clin Appl Thrombosis Hemostasis 1995, 1:3-23.
148. Di Paola J, Nugent D, Young G Current therapy for rare factor deficiencies. Haemophilia 2001, 7(Suppl):16-22.
149. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophilia Centre Doctor's Organization (UKHCDO). Br J Haematol 2000, 111:78-90.
150. Hemophilia of Georgia Protocols for the treatment of hemophilia and von Willebrand disease. Hemophilia 2000, 6(Suppl 1):84-93.
151. Hoffman M, Monroe DM A cell-based model of hemostasis. Thrombosis Haemostasis 2001, 85:958-965.
152. Hoyer LL Hemophilia A. N Engl J Med 1994, 330:38-47.
153. Mannucci P Treatment of Von Willebrand disease. N Engl J Med 2004, 351:683-694.
154. Mannucci PM Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988, 72:1449-1455.
155. Baker WF Thrombolytic therapy clinical application. Hematol Oncol Clin North Am 2003, 17:283-311.
156. Bick RL Antiphospholipid thrombosis syndrome. Hematol Oncol Clin North Am 2003, 17:115-147.
157. Bick RL Prothrombin G 20210A mutation, heparin cofactor II, protein C and protein S defects. Hematol Oncol Clin North Am 2003, 17:9-36.
158. Crowter MA, Kelton JG Congenital thrombophilic states associated with venous thrombosis. A qualitative overview and proposed classification system. Ann Intern Med 2003, 138:128-134.
159. Hoppe C, Matsunaga A Pediatric thrombosis. Pediatr Clin North Am 2002, 49:1257-1283.
160. Kwann HC, Nabhan C Hereditary and acquired defects in the fibrinolytic system associated with thrombosis. Hematol Oncol Clin North Am 2003, 17:103-114.
161. Levine JS, Branch W, Rauch J Antiphospholipid syndrome. New Engl J Med 2002, 346:752-763.
162. Meinardi JR, Middeldorp S, De Kam PJ, et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Brit J Haematol 2002, 116:625-633.
163. Selighsohn U, Lubertsky A Genetic susceptibility to venous thrombosis. N Engl J Med 2001, 344:1222-1231.
164. Whiteman T, Hassouna HI Hypercoagulable states. Hematol Oncol Clin North Am 2000, 14:355-377.
165. French J, Camitta BM The Spleen. Nelson Textbook of Pediatrics 2004, Elsevier, New York. 17th ed. R. Behrman, R.M. Kliegman, H.B. Jenson (Eds.).
166. Leung AKC, Robson WLM Childhood cervical lymphadenopathy. J Pediatr Health Care 2004, 18:3-7.
167. Link MP, Donaldson SS The lymphomas and lymphadenopathy. Nathan and Oski's Hematology of Infancy and childhood 2003, WB Saunders, Philadelphia. 6th ed.
168. Shurin SB The Spleen and its disorders. Hematology: Basic Principles and Practice 2000, Churchill Livingstone, London. 3rd ed. R. Hoffman, E.J. Benz, S.J. Shattil, B. Furie, H.J. Cohen, L.E. Silberstein (Eds.).
169. Twist CJ, Link MP Assessment of lymphadenopathy in children. Pediatr Clin North Am 2002, 49:1009-1025.
170. -, CD8-T, cells (α/β-DNTCs) in humans with autoimmune lymphoproliferative syndrome. Clin Immun 2002, 104:21-30.
171. Bleesing JJH, Straus SE, et al. Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival. Pediatr Clin North Am 2000, 47:1291-1310.
172. Chiocchetti A, Indelicato M, et al. High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation. Blood 2004, 103:1376.
173. Cohen JI Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases. Semin Hematol 2003, 40:116.
174. Ganne V., Siddiqi N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 2003, 17:417.
175. Garrett TJ, Chadburn A. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubcin-vincristine-prednisone chemotherapy. Cancer 1993, 72:2782-2785.
176. Hsueh C, Gonzalez-Crussi F, Murphy SB Testicular angiocentric lymphoma of post thymic T-cell type in a child with T-cell acute lymphoblastic leukemia in remission. Cancer 1993, 72:1801-1805.
177. Medcinos LJ, Harris NL Immunohistologic analysis of small lymphocytic infiltrates of the orbit and conjunctiva. Hum Pathol 1990, 21:1126-1131.
178. Paulli M, Berti E, Rosso R, Boveri E, et al. CD30/Ki-1 positive lymphoproliferative disorders of the skin-clinicopathological correlation and statistical analysis of 86 cases: a multicentric study of the European Organization of Research and treatment of cancer cutaneous lymphoma project groups. J Clin Oncol 1995, 13:1343-1354.
179. Peiper SC Angiocentric lymphoproliferative disorders of the respiratory system: incrimination of Epstein-Barr virus in pathogenesis. Blood 1993, 82:687-690.
180. Peterson BA, Frizzera G Multicentric Castleman's disease. Semin Oncol 1993, 636-647.
181. Seemayer TA, Gross TG, et al. X-linked lymphoproliferative diseases; twenty-five years after the discovery. Pediatr Res 1995, 38:471-478.
182. Steinberg AD, Seldin MF, Jaffe ES, Smith MR, et al. Angioimmunoblastic lymphadenopathy with dysproteinemia. Ann Intern Med 1998, 108:575-584.
183. Straathof KCM, Bollard CM, et al. Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist 2003, 8:83-98.
184. Sumegi J., Huang D., et al. Correction of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000, 96:3118-3125.
185. Tsatalas C, Margaritis D, et al. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with flud arabine. Acta Haematol 2001, 105:106-108.
186. Uphouse WJ, Woods JC Angioimmunoblastic lymphadenopathy with dysproteinemia. Cancer 1987, 60:2161-2164.
187. Van der Werff Ten Bosch J, Schotte P, et al. Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations. Br J Haematol 2002, 117:176-188.
188. Zirbel GM, Gellis SE, Kadin ME, Esterly NB Lymphomatoid papulosis in children. J Am Acad Dermatol 1995, 33:741-748.
189. Arico M, Biondi A, et al. Juvenile myelomonocytic leukemia. Blood 1997, 90:479-488.
190. Barnard DR, Lange B, et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood 2002, 100:427-434.
191. Flotho C, Valcmonica S, et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999, 13:32-37.
192. Hasle H, Fenu S, et al. International prognostic scoring system for childhood MDS and JMML. Leukemia 2000, 14:968.
193. Hasle H, Niemeyer C Myelodysplastic syndrome and juvenile myelomonocytic leukemia in children. The Myelodysplastic Syndromes: Pathophysiology and Clinical Management 2002, 299-344. Marcel Dekker, New York. J.M. Bennett (Ed.).
194. Kang JH, Shin HY, et al. Novel regimen for treatment of juvenile myelomonocytic leukemia (JMML). Leukemia Res 2004, 28:167-170.
195. Lange BJ, Kobrinsky N, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia, and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood 1998, 91:608-615.
196. Luna-Fineman S, Shannon KM, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood 1999, 93:459-466.
197. Macmillan ML, Davies SM, et al. Haematopoietic cell transplantation in children with juvenile myelomonocytic leukemia. Br J Haematol 1998, 103:552-558.
198. Passamore SJ, Hann CA, et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 1995, 85:1742-1750.
199. Woods WG, Barnard DR, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome. J Clin Oncol 2002, 20:434-440.
200. Carella AM, Beltrami G, et al. Allografting in chronic myeloid leukemia. Semin Hematol 2003, 72-78.
201. Deininger MWN, O'Brien SG, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003, 21:1637-1647.
202. Sacchi S, Kantarjian HM, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase. Analysis of the results of the first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999, 86:2632-2641.
203. Sattler M, Griffin JD Molecular mechanisms of translocation by the BCR-ABL oncogene. Semin Hematol 2003, 40:4-10.
204. Schwartz J, Pinilla-Ibarz J, et al. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. Semin Hematol 2003, 40:87-96.
205. Sekhar M, Pretice HG, et al. Idiopathic myelofibrosis in children. Br J Hematol 1996, 93:394-397.
206. Shet AS, Jahangir BN, et al. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 2002, 16:402-414.
207. Areci RJ Progress and controversies in the treatment of pediatric acute myelogenous leukemia. Curr Opin Hematol 2002, 9:353-360.
208. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MC, Johnston K, Erdmann GR, Gold S, Heerema NA, Hutchinson RJ, Provisor A, Trigg ME Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003, 101:3809-3817.
209. Cavé H, Bosch JWDW, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thelemans K, Grandchamp B, Vilmer E Clinical significance of minimal residual disease in childhood ALL. N Engl J Med 1998, 339:591-598.
210. Chessells JM Relapsed lymphoblastic leukemia in children: a continuing challenge. Br J Haematol 1998, 102:423-438.
211. Clark JJ, Smith FO, Arceci RJ Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies. Curr Opin Hematol 2003, 10:31-39.
212. de Boton S, Coiteux V, Chevret S, Rayon C, Vilmer E, et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol 2004, 15(22):1404-1412. (8).
213. Gaynon PS, Qu RP, Chappell RJ, Willoughby RLN, Tubergen DG, Steinherz PG, Trigg ME Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse-the Children's Cancer Group experience. Cancer 1998, 82:1387-1395.
214. Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sathei HN, Hammond GD, Bleyer WA Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000, 14:2223-2233.
215. Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Salan SE, Asselin BL Childhood T-cell acute lymphoblastic leukemia: the Dana Farber Cancer Institute. Acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003, 21:3616-3622.
216. Golub TR, Areci RJ Acute myelogenous leukemia. Principles and Practice of Pediatric Oncology 2002, 545-590. Lippincott-Williams and Wilkin, Philadelphia. P.A. Pizzo, D.G. Poplack (Eds.).
217. Harris RE, Sather HN, Feig SA High dose cytosine arabinoside and l-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience. Med Pediatr Oncol 1998, 30:233-239.
218. Margolin JF, Poplack DG Acute lymphoblastic leukemia. Principles and Practice of Pediatric Oncology 2002, 489-544. Lippincott-Williams and Wilkin, Philadelphia. P.A. Pizzo, D.G. Poplack (Eds.).
219. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM, Gaynon PS Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998, 338:1663-1671.
220. Patte C, Auperin A, Michon J, Behrendt H, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B cell lymphomas and L3 leukemia. Blood 2001, 97:3370-3379.
221. Pui CH NCCN pediatric acute lymphoblastic leukemia practice guidelines. Oncology 1996, 10:1787-1794.
222. Pui CH, Gaynon PS, Boyett JM, Chesells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DO, Vilmer E, Schrappe M, Camitta B Outcome of treatment in childhood acute-lymphoblastic leukemia with rearrangements of the 11q23 chromosomal region. Lancet 2002, 359:1909-1915.
223. Pui CH, Relling MV, Downing JR Mechanisms of disease: acute lymphoblastic leukemia. N Engl J Med 2004, 350:1535-1548.
224. Ritchey AK, Pollock BH, Lauer SJ, Andejeski Y, Buchanan GR Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 1999, 17:3745-3752.
225. Rubnitz JE, Look AT Molecular genetics of childhood leukemia. J Pediatr Hematol Oncol 1998, 20:1-11.
226. Rubnitz JE, Pui CH Recent advances in the treatment and understanding of childhood acute lymphoblastic leukemia. Cancer Treatment Rev 2003, 29:31-44.
227. Sievers EL Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). Blood Cells Mol Dis 2003, 31:7-10.
228. Silvermann LB, Sallen SE Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Curr Opin Hematol 2003, 10:290-296.
229. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996, 14:18-24.
230. Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. Cancer 1993, 72:3120-3130.
231. Stevens RF, Hahn IM, Wheatley K, Grayon RG Marked improvements in outcome with chemotherapy alone in paediatric acute leukemia: results of the United Kingdom Medical Research Councils 10 th AML trial. Br J Haematol 1998, 101:130-140.
232. Vardiman JW, Harris NL, Brunning RD The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2300.
233. Webb KH, Harison G, Stevens RF, Gibson BG, Hann IM, Wheatley K Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001, 98:1714-1720.
234. Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA Mitoxanthrone cytarabine induction, high-dose cytarabine and etoposide intensification for pediatric patients with relapsed or refactory acute myeloid leukemia. Children's Oncology Study Group 2951. J Clin Oncol 2003, 21:2940-2947.
235. Wofford MM, Smith SD, Shuster JJ, Johnson W, Buchanan GR, Wharam MD, Richey AK, Rosen D, Haggard ME, Golembe BL, Rivera GK Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1992, 10:624-630.
236. Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S, Gold S, Barnard DR, DeSwarte J, Dusenbery K, Kalousek D, Arthur DC, Lange BJ Timedsequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996, 87:4979-4989.
237. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, Dusenbery K, DeSwarte J, Arthur DC, Lange BJ, Kobrinsby NL A comparison of allogeneic bone marrow transplantation and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group. Blood 2001, 97:56-61.
238. Ambinder R, Mann R Epstein-Barr encoded RNA in situ hybridization. Hum Pathol 1994, 25:602.
239. Aygun B, Karakas SP, Leonidas J, Valderrama E, Karayalcin G Reliability of splenic index to assess splenic involvement in pediatric Hodgkin's disease. J Pediatr Hematol Oncol 2004, 26:74.
240. Bonadonna G, Valagussa P, Santoro A Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: a report of 8-year results. Ann Intern Med 1986, 104:746.
241. Carbone PP, Kaplan HS, Husshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971, 31:1860.
242. De Vita VTJ, Canellos G, Moxley J A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer 1972, 30:1495.
243. Donaldson SS, Hudson M, Lamborn R, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin disease: results of a prospective trial. J Clin Oncol 2002, 20:3081.
244. Harris NL, Jaffe ES, Diebold J, et al. Wood Health Organization classification of neoplastic diseases of hemapoietic and lymphoid tissues: report of the clinical of neoplastic diseases of hemapoietic and lymphoid tissues. JCO 1999, 17:3835.
245. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neo plasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361.
246. Kadin ME, Liebowitz Cytokines and cytokine receptors in Hodgkin's diseases. Hodgkin's Disease 1999, 139-157. Lippincott Williams & Wilkins, Philadelphia. P.M. Mauch, J. Armitrage, V. Diehl, R.T. Hoppe, L.M. Weiss (Eds.).
247. Karayalcin G, Behm FG, Geiser PW, et al. Lymphocyte predominant Hodgkin's disease; clinicopathologic features and results of treatment-the Pediatric Oncology Group experience. Med Pediatr Oncol 1997, 29:516.
248. Lukes RJ, Butler JJ The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966, 26:1063.
249. Nachman JB, Sposo R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete responte to chemotherapy. J Clin Oncol 2002, 20:3765.
250. Rini JN, Manalili EY, Hoofman M, Karyalcin G, Mechatra B, Thomas B, Palestro CJ F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Clin Nucl Med 2002, 27:572.
251. Ruhl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Bio Phys 2001, 51:1209.
252. Schellong G Treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric Study Group. Baillieres Clin Haematol 1996, 9:619.
253. Schmitz N, Pfister B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous stem-cell transplantation for relapsed chemo-sensitive Hodgkin's disease. A randomized trial. Lancet 2002, 341:1051.
254. Stein H, Diehl V, Marafieti T, et al. The nature of Reed-Sternberg cells, lymphocytic and histiocytic cells and their molecular biology in Hodgkin's disease. Hodgkin's Disease 1999, 121-137. Lippincott Williams & Wilkins, Philadelphia. P.M. Mauch, J. Armitage, V. Diehl, R.T. Hoppe, L.M. Weiss (Eds.).
255. Weiner MA, Leventhal BG, Marcus R, et al. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 1991, 9:1591.
256. Brugieres L, Quartier P, Le Deley MC, et al. Relapses of childhood anaplastic largecell lymphoma: treatment results in a series of 41 children-a report from the French Society of Pediatric Oncology. Ann Oncol 2000, 11:53-58.
257. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized FAB LMB 96 international study in children and adolescents with advanced B-NHL: patients with L3 leukemia/CNS have an excellent prognosis. Proc Am Soc Clin Oncol 2003, 22:796.
258. Cairo MS, Sposto R, Perkins S, et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group Experience. Br J Haematol 2003, 120:660-670.
259. Diebold J World Health Organization classification of malignant lymphomas. Exp Oncol 2001, 23:101-103.
260. Gerrard M, Cairo M, Weston C, et al. Results of the FAB international study in children and adolescents with localized, resected B cell lymphoma. Proc Am Soc Clin Oncol 2003, 22:795.
261. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97(10):2998-3003.
262. Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB Treatment of children and young adults with early stage non-Hodgkin's lymphoma. New Engl J Med 1997, 337:1259-1266.
263. Magrath IT Malignant non-Hodgkin's lymphomas in children. Principles and Practice of Pediatric Oncology 2002, Lippincott Williams & Wilkins, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
264. Neth O, Seidemann K, Jansen P, et al. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol 2000, 35:20-27.
265. Patte C, Gerrard M, Auperin A, et al. Results of the randomized international trial FAB LMB 96 for the "intermediate risk" childhood and adolescent B cell lymphoma: reduced therapy is efficacious. Proc Am Soc Clin Oncol 2003, 22:796.
266. Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM Group report. Blood 2000, 95(2):416-421.
267. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic largecell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001, 97(12):3699-3706.
268. Balmaceda C, Heller G, Rosenblum M, Diez B, Villablance JG, Kellie S, Maher P, Vlamis V, Walker RW, Leibel S, Finlay JL Chemotherapy without irradiation-a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. J Clin Oncol 1996, 14:2908-2915.
269. Biegel JA Genetics of pediatric central nervous system tumors. J Pediatr Hematol Oncol 1997, 19:492-501.
270. Duffner PC, Horowitz ME, Krischer JP, Friedman HS, Burger PC, Cohen ME, Sanford RA, Mulhern RK, James HE, Freeman CR, Seidel FG, Kun LE Postoperative chemotherapy and delayed radiation in children less than 3 years of age with malignant brain tumors. N Engl J Med 1993, 328:1725-1731.
271. Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg 1999, 90:237-250.
272. Halperin EC, Constine LS, Tarbell NJ, Kun LE Pediatric Radiation Oncology 1999, Lippincott Williams and Wilkins, Philadelphia. 3rd ed.
273. Mason WP, Growas A, Halpern S, Dunkel IJ, Garvin J, Heller G, Rosenblum M, Gardner S, Ly den D, Sands S, Puccetti D, Lindsley K, Merchant TE, O'Malley B, Bayer L, Petriccione M, Allen J, Finlay JL Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998, 16:210-221.
274. MacDonald TJ, Rood BR, Santi MR, Vezina G, et al. Advances in the diagnosis, molecular genetics and treatment of pediatric embryonal CNS tumors. Oncologist 2003, 8:174-186.
275. Packer RJ, Ater J, Allen D, Phillips P, Geyer R, Nicholson HS, Jakacki R, Kurczynski E, Needle M, Finlay J, Reaman G, Boyett JM Carboplatin and vincristine chemotherapy for children with new ly diagnosed progressive low-grade glioma. J Neurosurg 1997, 86:747-754.
276. Reddy AT, Packer RJ Pediatric central nervous system tumors. Curr Opin Oncol 1998, 10:186-193.
277. Srother D, Pollack I, Fisher P, Hunter J, et al. Tumors of the central nervous system. Principles and Practice of Pediatric Oncology 2002, Lippincott Williams and Wilkins, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
278. Stupp R, Dietrich P, Kraljevic SO, Pica A, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide, followed by adjuvant temozolomide. J Clin Oncol 2002, 20:1375.
279. Bessho F Colloquy on neuroblastoma screening: is there a future for neuroblastoma mass screening?. Med Pediat Oncol 1998, 31:106-110.
280. Bowman LC, Castleberry RP, Cantor A, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst 1997, 89(5):373-380.
281. Cheung NK Monoclonal antibody-based therapy for neuroblastoma. Curr Oncol Rep 2000, 2(6):547-553.
282. Cojean N, Entz-Werle N, Eyer D, et al. Dumbbell nephroblastoma: an uncommon cause of spinal cord compression. Arch Pediatr 2003, 10(12):1075-1078.
283. Cooper R, Khakoo Y, Matthay KK, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 2001, 36(6):623-629.
284. Hsu LL, Evans AE, D'Angio GJ Hepatomegaly in neuroblastoma stage 4S: criteria for treatment of the vulnerable neonate. Med Pediatr Oncol 1996, 27(6):521-528.
285. Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy and histology in 110 infants with stage D(S) neuroblastoma: the Pediatric Oncology Group experience-a Pediatric Oncology Group study. J Oncol 1998, 16:2007-2017.
286. Kerbl R, Urban CE, Ambros IM, et al. Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors. J Clin Oncol 2003, 21(22):4228-4234.
287. Kushner BH, Cheung NK, LaQuaglia MP, et al. International neuroblastoma staging system stage I neuroblastoma: a prospective study and literature review. J Clin Oncol 1996, 14(7):2174-2180.
288. Matthay KK Stage 4S neuroblastoma: what makes it special?. J Clin Oncol 1998, 16:2003-2006.
289. Matthay KK, Brisse H, Couanet D, et al. Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer 2003, 98(1):155-165.
290. 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003, 21(13):2486-2491.
291. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol 1998, 16(4):1256-1264.
292. Pollono D, Tomarchia S, Drut R, et al. Spinal cord compression: a review of 70 pediatric patients. Pediatr Hematol Oncol 2003, 20(6):457-466.
293. Reynolds CP, Villablanca JG, Stram DO, et al. 13-cis-retinoic acid after intensive consolidation therapy for neuroblastoma improves event-free survival: a randomized Children's Cancer Group (CCG) study. Proc Am Soc Clin Oncol 1998, 17(A5):2a.
294. Rubie H, Coze C, Plantaz D, et al. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy. Br J Cancer 2003, 89(9):1605-1609.
295. Seeger RC, Reynolds CP, Gallego R, et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2000, 18(24):4067-4076.
296. Tchirkov A, Paillard C, Halle P, et al. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma. J Hematother Stem Cell Res 2003, 12(4):435-442.
297. Woods WG, Tuchman M, Bernstein M, Lemieux B Screening infants for neuroblastoma does not reduce the incidence of poor-prognosis disease. Med Pediatr Oncol 1998, 31:450-454.
298. Abu-Gosh AM, Krailo MD, Goldman SC, Slack RS, Davenport V, Morris E, Laver JH, Reaman GH, Cairo W Ifosfamide, carboplatin and etoposide in children with poor risk relapsed Wilms tumor: a Children's Cancer Group report. Ann Oncol 2002, 13:460-469.
299. Beckwith JB, Zuppan CE, Browning NG, Moksness J, Breslow NE Histological analysis of aggressiveness and responsiveness in Wilms' tumor. Med Pediatr Oncol 1996, 27:422-428.
300. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748-1756.
301. D'Angio GJ Pre or post operative treatment for Wilms tumor? Who, what, when, where, how, why and which. Med Pediatr Oncol 2003, 41:545-549.
302. Dome JS, Coppes MJ Recent advances in Wilms' tumor genetics. Curr Opin Pediatr 2002, 14:5-11.
303. Green DM Wilms' tumor. Eur J Cancer 1997, 33:409-418.
304. Green DM, Beckwith JB, Breslow NE, Faria P, Moksness J, Finkelstein JZ, Grundy P, Thomas PRM, Kim T, Shochat S, Haase G, Ritchey M, Kelalis P, D'Angio GJ Treatment of children with stage II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1994, 12:2126-2131.
305. Green DM, Breslow NE, Beckwith JB, Finkelstein JZ, Grundy PE, Thomas PRM, Kim T, Shochat SJ, Haase GM, Ritchey MC, Kelalis PP, D'Angio GJ Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998, 16:3744-3751.
306. Green DM, Breslow NE, Beckwith JB, Finkelstein JZ, Grundy PE, Thomas PRM, Kim T, Shochat SJ, Haase GM, Ritchey MC, Kelalis PP, D'Angio GJ Comparison between single dose and divided dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998, 16:237-248.
307. Green DM, D'Angio GJ, Beckwith JB, Breslow NE, Grundy PE, Ritchey MI, Thomas PRM Wilms' tumor. CA Cancer J Clin 1996, 46:46-63.
308. Kremens B, Gruhn B, Klingebiel T, Hasan C, Laws HJ, Koscielniak E, Hero B, Selle B, Niemeyer G, Finckenstein FG, Schulz A, Wawer A, Zinti F, Graf N High dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transpl 2002, 30:893-898.
309. Merguerian PA Pediatric genitourinary tumors. Curr Opin Oncol 2003, 15:222-226.
310. Pein F, Michon J, Valteau-Couanet D, Quintana E, Frappaz D, Vannier JP, Philip T, Bergeron C, Baranzelli MC, Thyss A, Stephan JL, Boutard P, Gentet JC, Zucker JM, Tournadi MF, Hartman O High dose melphalan, etoposide, and carboplatin followed by autologous stem cell rescue in pediatric high risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J Clin Oncol 1998, 16:3295-3301.
311. Pein F, Tournade MF, Zucker JM, Brunat-Mentigny M, Deville A, Boutard P, Dusol F, Gentet JC, Legall E, Mechinaud F, Plouvier E, Plantaz D, Pautard B, Rubie H, Lemerle J Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor, a phase II study by the French Society of Pediatric Oncology. J Clin Oncol 1994, 12:931-936.
312. Petruzzi MJ, Green DM Wilms' tumor. Pediatr Clin North Am 1997, 44:939-951.
313. Blakely M, Spurbeck W, Pappo A, et al. The impact of margin of resection on out-come in pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Pediatr Surg 1999, 34:672.
314. Breneman J, Lyden E, Pappo A, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003, 21:78.
315. Cecchetto G, Modesto C, Alaggio R, et al. Fibrosarcoma in pediatric patients: results of the Italian Cooperative Group Studies (1979-1995). J Surg Oncol 2001, 78:225.
316. Crist W, Anderson J, Meza J, et al. Intergroup Rhabdomyosarcoma Study IV: results for patients with nonmetastatic disease. J Clin Oncol 2001, 19:3091.
317. Lawrence W, Gehan E, Hays D, et al. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol 1987, 5:46.
318. Miser J, Pappo A, Triche T, et al. Other soft tissue sarcomas of childhood. Principles and Practice of Pediatric Oncology 2002, Lippincott Williams & Wilkins, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
319. Wexler L, Crist W, Helman L Rhabdomy osarcoma and the undifferentiated sarcomas. Principles and Practice of Pediatric Oncology 2002, Lippincott Williams & Wilkins, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
320. Bacci G, Briccoli A, Ferrari S, Longhi A, Mercuri M, Capanna R, Donati D, Lari S, Forni C, DePaolis M Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer 2001, 37:2030-2039.
321. Bielack SS, Kampf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkleman W, Zoubek A, Jurgens H, Winkler K Prognostic factors in high grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20(3):776-790.
322. Ferguson WS, Goorin AM Current treatment of osteosarcoma. Cancer Invest 2001, 19(3):292-315.
323. Gaetano B, Forni C, Ferrari S, Longhi A, Bertoni F, Mercuri M, Donati D, Capanna R, Bernini G, Briccoli A, Setola E, Versari M Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol 2003, 25(11):845-853.
324. Goorin AM, Harris MB, Berstein M, Ferguson W, Devidas M, Siegal GP, Gebhardt C, Schwartz CL, Link MP, Grier HE Phase II/III trial of etoposide and high dose ifosfamide in newly diagnosed metastatic osteosarcoma: a Pediatric Oncology Group trial. J Clin Oncol 2002, 20(2):426-433.
325. Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE, Link MP Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for non-metastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003, 21(8):1574-1580.
326. Gorlick R, Meyers PA Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J Pediatr Hematol Oncol 2003, 25(11):840-841.
327. Gurney JG, Swensen AR, Bukterys M Malignant bone tumors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. NIH Pub No 99-4649 1999, 99-110. National Cancer Institute, SEER Program, Bethesda, MD.
328. Link MP, Genhardt MC, Meyers PA Osteosarcoma. Principles and Practice of Pediatric Oncology 2003, Lippincott-Raven, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
329. Donaldson SS Ewing sarcoma: radiation dose and target volume. Pediatr Blood Cancer 2004, 42:471-476.
330. Gaetano B, Ferrari S, Bertoni F, Rimondidni S, Longhi A, Bacchini P, Forni C, Manfrini M, Donati D, Picci P Prognostic factors in nonmetastatic Ewing sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ostopedico Rizzoli. J Clin Oncol 2000, 18(1):4-11.
331. Ginsberg JP, Woo SY, Johnson ME, Hicks MJ, Horowitz ME Ewing sarcoma family of tumors: Ewing sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. Principles and Practice of Pediatric Oncology 2003, Lippincott-Raven, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
332. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donalson SS, Moore S, Rausen AR, Vietti TJ, Miser JS Addition of ifosfamide and etoposide to standard chemotherapy for Ewing sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003, 348:694-701.
333. Gurney JG, Swensen AR, Bukterys M Malignant bone tumors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. NIH Pub No 99-4649 1999, 99-110. National Cancer Institute, SEER Program, Bethesda, MD.
334. Kushner BH, Meyers PA How effective is dose intensive/myeloablative therapy against Ewing sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering exprience and a literature review. J Clin Oncol 2001, 19(3):870-880.
335. Meyers PA, Krailo MD, Ladanyi M, Chan K, Sailer SL, Dickman PS, Baker DL, Davis JH, Gerbing RB, Grovas A, Herzog CE, Lindsley KL, Liu-Mares W, Nachman JB, Sieger L, Wadman J, Gorlick RG High-dose melphalan, etoposide, total-body irradiation and autologous stem-cell reconstitution as consolidation therapy does not improve prognosis. J Clin Oncol 2001, 19(11):2812-2820.
336. Ambruso DR, Hays T, Zwartjes WJ, Tubergen DG, Favara BE Successful treatment of lymphohistiocytic reticulosis with phagocytosis withepipodophyllotoxin VP 16-213. Cancer 1980, 45:2516-2520.
337. Arico M, Allen M, Brusa S, Clementi R, Pende D, Maccario R, Moretta L, Danesino C Haemophagocytic lymphohistiocytosis: proposal of a diagnostic algorithm based on perforin expression. Br J Haematol 2002, 119:180-188.
338. Arico M, Egeler RM Clinical aspects of Langerhans' cell histiocytosis. Hematol Oncol Clin North Am 1998, 12:247-258.
339. Broadbent V, Gadner H Current therapy for Langerhans' cell histiocytosis. Hematol Oncol Clin North Am 1998, 12:327-337.
340. Dufoureq-Lagelouse R, Pastural E, Barrat FJ, Feldmann J, Le Deist F, Fischer A, De Saint Basile G Genetic basis of hemophagocytic lymphohistiocytosis syndrome (Review). Int J Mol Med 1999, 4:127-133.
341. Egeler RM, D'Angio G Langerhans' cell histiocytosis. J Pediatr 1995, 127:1-11.
342. Favara BE, Feller AC, with members of the WHO Committee on Histiocytic/Reticulum Cell Proliferations, Pauli M, et al. Contemporary classification of histiocyte disorders. Med Pediatr Oncol 1997, 29:157-166.
343. Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C, Lambert N, Ouachee-Chardin M, Chedeville G, Tamary H, Minard-Colin V, Vilmer E, Blanche S, Le Deist F, Fischer A, de Saint Basile G Munc 13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 2003, 115:461-473.
344. Grois NG, Favara BE, Mostbeck GH, Prayer D Central nervous system disease in Langerhans' cell histiocytosis. Hematol Oncol Clin North Am 1998, 12:287-305.
345. Grom AA, Passo M Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr 1996, 129:630-632.
346. Henter JI, Arico M, Elinder G, Imashuku S, Janka G Familial hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 1998, 12:417-433.
347. Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002, 100:2367-2373.
348. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI Infection and malignancy associated hemophagocytic syndromes. Hematol Oncol Clin North Am 1998, 12:435-443.
349. Ladisch S, Gadner H, Arico M, Broadbent V, Grois N, Jacobson A, Komp D, Nicholson HS LCH-1: a randomized trial of etoposide versus vinblastine in disseminated Langerhans' cell histiocytosis. Med Pediatr Oncol 1994, 23:107-110.
350. Ladisch S, Jaffe ES The histiocytoses. Principles and Practice of pediatric Oncology 1997, 615-631. Lippincott-Raven, Philadelphia. 3rd ed. P.A. Pizzo, D.G. Poplack (Eds.).
351. Lipton JM, Arceci RJ Histiocytic disorders. Hematology: Basic Prinicples and Practice 2004, Churchill Livingstone, New York. 4th ed. R. Hoffman, E.J. Benz, S.J. Shattil, B. Furie, H.J. Cohen, L.E. Silberstein, P. McGlave (Eds.).
352. Malone M The histiocytoses of childhood. Histopathology 1991, 19:105-119.
353. Munn S, Chu AC Langerhans' cell histiocytosis of the skin. Hematol Oncol Clin North Am 1998, 12:269-285.
354. Murakami I, Gogusev J, Fournet JC, Glorion C, Jambert F Detection of molecular cytogenetic aberrations in Langerhans' cell histiocytosis of bone. Hem Pathol 2002, 33:555-560.
355. Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlehwaite JR, Whitington PF Association between liver transplantation for Langerhans' cell histiocytosis and development of post-transplant lymphoproliferative disease in children. J Pediatr 1997, 131:98-104.
356. Reiter A, Schrappe M, Tiemann M, Parwaresch R, Zimmerman M, Yakisan E, Dopfer R, Bucsky P, Mann G, Gadner H, Riehm H Successful treatment strategy for Ki-1 anaplastic large cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster Group studies. J Clin Oncol 1994, 12:899-908.
357. Ware R, Friedman HS, Kinney TR, Kurtzberg J, Chaffee S, Falletta JM Familial ery throphagocytic lymphohistiocytosis: late relapse despite continuous high-dose VP-16 chemotherapy. Med Pediatr Oncol 1990, 18:27-29.
358. William CL, McClain KL An update on clonality, cytokines, and viral etiology in Langerhans' cell histiocytosis. Hematol Oncol Clin North Am 1998, 12:407-416.
359. Abramson DH, Frank CM, Dunkel IJ A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmol 1999, 106(10):1947-1950.
360. Bunin GR, Meadows AT, Emanuel BS, Buckley JD, Woods WG, Hammond GD Preand postconception factors associated with sporadic heritable and nonheritable retinoblastoma. Cancer Res 1989, 49(20):5730-5735.
361. Dunkel IJ, Aledo A, Kernan NA, Kushner B, Bayer L, Gollamudi SV, Finlay JL, Abramson DH Successful treatment of metastatic retinoblastoma. Cancer 2000, 89(10):2117-2121.
362. Friedman DL, Himelstein B, Shields CL, Shields JA, Needle M, Miller D, Bunin GR, Meadows AT Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000, 18(1):12-17.
363. Gallie BL, Budning A, DeBoer G, Thiessen JJ, Koren G, Verjee Z, Ling V, Chan HS Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996, 114(11):1321-1328.
364. Hurwitz RL, Shields CL, Shields JA, Chevez-Barrios P, Hurwitz MY, Chintagumpala MM Retinoblastoma. Principles and Practice of Pediatric Oncology 2002, 825-846. Lippincott Williams and Wilkins, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
365. Knudson AG Cancer genetics. Am J Med Genet 2002, 111(1):96-102.
366. Moll AC, Imhof SM, Schouten-Van Meeteren AY, Kuik DJ, Hofman P, Boers M Second primary tumors in hereditary retinoblastoma: a register-based study, 1945-1997: is there an age effect on radiation-related risk?. Ophthalmol 2001, 108(6):1109-1114.
367. Murphree AL, Villablanca JG, Deegan WF, Sato JK, Malogolowkin M, Fisher A, Parker R, Reed E, Gomer CJ Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996, 114(11):1348-1356.
368. Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide, and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer 1997, 33(14):2368-2375.
369. Rodriguez-Galindo C, Wilson MW, Haik BG, Lipson MJ, Cain A, Merchant TE, Kaste S, Pratt CB Treatment of metastatic retinoblastoma. Ophthalmol 2003, 110(6):1237-1240.
370. Wong FL, Boice JD, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, Goldman MB, Seddon JM, Tarbell N, Fraumeni JF, Li FP Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997, 278(15):1262-1267.
371. Ablin AR, Krailo MD, Ramsay NKC, Malogolowkin MH, Issacs H, Raney RB, Adkins J, Hays DM, Benjamin DR, Grosfeld JL, Leiken SL, Deutsch M, Hammond GD Results of treatment of malignant germ cell tumors in 93 children: a report from the Children's Cancer Study Group. J Clin Oncol 1991, 9:1782-1792.
372. Balmaceda C, Heller G, Rosenblum M, et al. Chemotherapy without irradiation: a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. J Clin Oncol 1996, 12:2908-2915.
373. Beyer J, Kramar R, Mandanas W, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996, 14:2638-2645.
374. Cushing B, Giller R, Lauer S, et al. Comparison of high dose or standard dose cisplatin with etoposide and bleomycin (HDPEB versus PEB) in children with stage I-IV extragonadal malignant germ cell tumors (MGCT). Proc Am Soc Clin Oncol 1998, 2017.
375. Cushing B, Giller R, Marina N, et al. Results of surgery alone or surgery plus cisplatin, etoposide and bleomycin (PEB) in children with localized gonadal malignant germ cell tumor (MGCT): a pediatric intergroup report (POG 9048/CCG 8891). Proc Am Soc Clin Oncol 1997, 16:511a.
376. Cushing B, Perlman E, Marina N, Castleberry RP Germ cell tumors. Principles and Practice of Pediatric Oncology 2002, Lippincott-Raven, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
377. Hawkins EP Pathology of germ cell tumors in children. Crit Rev Oncol Hematol 1990, 10:165-179.
378. Malogolowkin MH, Ortega JA, Krailo M, Gonzalez O, Hossein Mahour G, Landing BH, Siegel SE Immature teratomas: identification of patients at risk for malignant recurrence. J Natl Cancer Inst 1989, 81:870-874.
379. Marina NM, Cushing B, Giller R, Cohen L, et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: a Pediatric Oncology Group/Children's Cancer Group intergroup study. J Clin Oncol 1999, 17:2137-2143.
380. Motzer RJ, Mazumdar M, Bosl GJ, et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patient with poor-risk germ cell tumors. J Clin Oncol 1997, 15:2546-2552.
381. Nichols CG, Fox EP Extragonadal and pediatric germ cell tumors in children. North Am Hematol Oncol Clin 1990, 5:1189-1209.
382. Nichols CR, Williams S, Loehrer PJ, et al. A randomized study of cisplatin dose intensity in advanced germ cell tumors: a southeastern and southwest oncology group protocol. J Clin Oncol 1991, 9:1163-1172.
383. Teinturier C, Gelez J, Flamant V, Habrand SL, Lemerle S Pure dysgerminom a of the ovary in childhood: treatment results sequelae. Med Pediatr Oncol 1994, 23:1-7.
384. Bilk P, Superina R Transplantation for unresectable liver tumors in children. Transplan Proc 1997, 29:2834-2836.
385. Buckley JD, Sather H, Ruccione K, Rogues PCJ, Haas JG, Henderson BE, Hammond GD A case control study of risk factors for hepatoblastoma: a report from the Children's Cancer Study Group. Cancer 1989, 64:1169-1176.
386. Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A Cisplatin, vincristine and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol 1993, 11:96-99.
387. Ortega JA, Douglass E, Feusner J, et al. A randomized trial of cisplatin, vincristine, 5-fluorouracil versus cisplatin/ doxorubicin IV continuous infusion for the treatment of hepatoblastoma: results from the Pediatric Intergroup Hepatoma study (CCG-8881/POG-8945). Proc Am Soc Clin Oncol 1994, 13:A 1421.
388. Ortega JA, Krailo MD, Haas JE, King DR, Ablin AR, Quinn JJ, Feusner J, Campbell JR, Lloyd DA, Cherlow J, Hammond GD Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Children's Cancer Study Group. J Clin Oncol 1991, 9:2167-2176.
389. Raney B Hepatoblastoma in children: a review. J Pediatr Hematol Oncol 1997, 19:418-422.
390. Tomilinson GE, Finegold MJ Tumors of the liver. Principles and Practice of Pediatric Oncology 2002, Lippincott-Raven, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
391. Anderson KC The role of the blood bank in hematopoietic stem cell transplantation. Transfusion 1992, 32(3):272-285.
392. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000, 342(14):998-1006.
393. Bearman SI, Lee JL, Baron AE, McDonald GB Treatment of hepatic veno-occlusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997, 89(5):737-744.
394. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA system, 1998. Hum Immunol 1999, 60(4):361-395.
395. Brunet S, Urbano A, Ojeda E, et al. Favourable effect of the combination of acute and chronic graft versus host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced hematological malignancies. Br J Haematol 2001, 114(3):544-545.
396. Champlin R, Khouri I, Kornblau S, et al. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am 1999, 13(5):1041-1057.
397. Champlin R, Khouri I, Kornblau S, et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 1999, 11(2):87-95.
398. Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. Ann Intern Med 1998, 128:975-981.
399. Gluckman E, Devergie A, Bourdeau EH, et al. Transplantation of umbilical cord blood in Fanconi's anemia. Nouv Rev Fr Hematol 1990, 32(6):423-425.
400. Gluckman E Umbilical cord blood hematopoietic stem cells; biology and transplantation. Curr Opin Hematol 1995, 2(6):413-416.
401. Guruangan S, Dunkel IJ, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998, 16(7):2486-2493.
402. Hongeng S, Krance RA, Bowman LC, et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukemia. Lancer 1997, 350(9080):767-771.
403. Levine JE, Harris RE, Fausto R, et al. A comparison of allogeneic and autologous bone marrow transplantation for symptomatic lymphoma. Blood 2003, 101(7):2476-2482.
404. Majolino I, Pearce R, Taghipour G, Goldstone AH Peripheral blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 1997, 15(2):509-517.
405. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy radiotherapy autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999, 341(16):1165-1173.
406. Mehta J, Powles R, Singhal S, et al. Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility. Bone Marrow Transpl 1996, 18(1):151-156.
407. Morrison VA, Peterson BA High-dose therapy and transplantation in non-Hodgkin's lymphoma. Semin Oncol 1999, 26(1):84-98.
408. Neudorf S, Sanders JE, Howells W, et al. The beneficial role of autologous bone marrow transplantation in the treatment of childhood acute myelogenous leukemia: a report from the Children's Cancer Group. Blood 1998, 92(Suppl 1):294a.
409. Porter DL, Antin JH The graft-versus-leukemia effects of allogeneic cell therapy. Ann Rev Med 1999, 50:369-386.
410. Rosenthal J, Sender L, Secola R, et al. Phase II trial of heparin prophylaxis for venoocclusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transpl 1996, 18:185-191.
411. Sable CA, Donowitz GR Infections in bone marrow transplant recipients. Clin Infect Dis 1994, 18:273-284.
412. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disesases. Blood 1998, 91(3):756-763.
413. Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease. Blood 2000, 95(6):1918-1924.
414. Woolfrey AE, Gooley TA, Sievers EL, et al. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome. Blood 1998, 92(10):3546-3556.
415. Zecco M, Prete A, Rondelli R, et al. Chronic graft versus host disease in children: incidence, risk factors, and impact on outcome. Blood 2003, 100(4):1192.
416. Alexander SW, Walsh TJ, Freifeld AG, Pizzo PA Infectious complications in pediatric cancer patients. Principles and Practice of Pediatric Oncology 2002, 1239-1284. Lippincott, Williams & Wilkins, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
417. Barnard DR, Friedman DL, Landier W, Larson-Tuttle C, Iacuone J Monitoring and management of drug toxicity. Supportive care of Children with Cancer. Current Therapy and Guidelines from the Children's Oncology Group 2004, 100-148. The Johns Hopkins University Press, Baltimore. 3rd ed. A.J. Altman (Ed.).
418. Bechard LJ, Adiv OE, Jaksic T, Duggan C Nutritional supportive care. Principles and Practice of Pediatric Oncology 2002, 1285-1300. Lippincott, Williams & Wilkins, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
419. Berde CB, Billett AL, Collins JJ Symptom management in supportive care. Principle and Practice of Pediatric Oncology 2002, 1301-1332. Lippincott, Williams & Wilkins, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
420. Feusner J, Hastings C Recombinant human erythropoietin in pediatric oncology: a review. Med Pediatr Oncol 2002, 39:463-468.
421. Gorlin JB Noninfectious complications of pediatric transfusion. Handbook of Pediatric Transfusion Medicine 2004, 317-325. Elsevier Academic Press, San Diego. C.D. Hillyer, R.G. Strauss, N.L.C. Luban (Eds.).
422. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.
423. Jamali F, Ness PM Infectious complications. Handbook of Pediatric Transfusion Medicine 2004, 329-339. Elsevier Academic Press, San Diego. C.D. Hillyer, R.G. Strauss, N.L.C. Luban (Eds.).
424. Logdberg LE Leukoreduced products: prevention of leukocy te-related transfusion-associated adverse effects. Handbook of Pediatric Transfusion Medicine 2004, 85-90. Elsevier Academic Press, San Diego. C.D. Hillyer, R.G. Strauss, N.L.C. Luban (Eds.).
425. Orudjev E, Lange BJ Evolving concepts of management of febrile neutropenic in children with cancer. Med Pediatr Oncol 2002, 39:77-85.
426. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000, 18(20):3558-3585.
427. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemias in patients with leukemia or lymphoma. J Clin Oncol 2001, 19(3):697-704.
428. Rheingold SR, Lange BJ Oncologic emergencies. Principles and Practice of Pediatric Oncology 2002, 1177-1204. Lippincott, Williams & Wilkins, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
429. Rizzo JD, Lichtin AE, Woolfs SH, et al. Use of epoetinin patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002, 100(7):2303-2320.
430. Rogers ZR, Aquino VM, Buchana GR Hematologic supportive care and hematopoietic cytokines. Principles and Practice of Pediatric Oncology 2002, 1205-1238. Lippincott, Williams & Wilkins, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
431. Sacks N, Ringwals-Smith K, Hale G Nutritional support. Supportive Care of Children with Cancer. Current Therapy and Guidelines from the Children's Oncology Group 2004, 243-261. The Johns Hopkins University Press, Baltimore. 3rd ed. A.J. Altman (Ed.).
432. Wolff LJ, Altman AJ, Berkow RL, Johnson FL The management of fever and neutropenia. Supportive Care of Children with Cancer. Current Therapy and Guidelines from the Children's Oncology Group 2004, 200-220. The Johns Hopkins University Press, Baltimore. 3rd ed. A.J. Altman (Ed.).
433. Zempsky WT, Schechter NL, Altman AJ, Weisman SJ The management of pain. Supportive Care of Children with Cancer. Current Therapy and Guidelines from the Children's Oncology Group 2004, 200-220. The Johns Hopkins University Press, Baltimore. 3rd ed. A.J. Altman (Ed.).
434. Beaty O, Hudson MM, Greenwald C, Luo X, Fang L, Wilmas JA, Thompson EI, Kun LE, Pratt CB Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol 1995, 13:603-609.
435. Bhatia S Late effects among survivors of leukemia during childhood and adolescence. Blood Cells Mol Dis 2003, 31:84-92.
436. Breslow NE, Takashina JR, Whitton JA, D'Angio GJ, Green DM Second malignant neoplasms following treatment of Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1995, 13:1851-1859.
437. Dreyer ZE, Blatt J, Bleyer A Late effects of childhood cancer and its treatment. Principles and Practice of Pediatric Oncology 2002, Lippincott, Williams and Wilkins, Philadelphia. 4th ed. P.A. Pizzo, D.G. Poplack (Eds.).
438. Friedman DL, Meadows AT Late effects of childhood cancer therapy. Pediatr Clin North Am 2002, 49:1063-1081.
439. Childhood Cancer Survivorship Improving Care and Quality of Life 2003, National Academic Press, Washington, DC. M. Hewitt, S.L. Weiner, J.V. Simone (Eds.).
440. Heym R, Hoeberlen V, Newton WA, Ragab AH, Raney RB, Teft M, Wharam M, Ensign LG, Mauera H Second malignant neoplasm in children treated for rhabdomy osarcoma. J Clin Oncol 1993, 11:262-270.
441. Hudson MH, Jones D, Boyelt J, Sharp GB, Pui CH Late mortality of long term survivours of childhood cancer. J Clin Oncol 1997, 15:2205-2213.
442. Hudson MH, Mertens AC, Yasui Y, Hobbie W, Chen H, Gurney JG, Yeazel M, Rechlites CJ, Marina N, Robinson LR, Oeffinger KC Health status of adult long term survivors of childhood cancer. A report from the Childhood Cancer Survivor Study. JAMA 2003, 290:1583-1592.
443. Iacuone JL, Steinherz L, Oblender MG, Bernard DR, Ablin AR Modifications for toxicity. Supportive Care of Children with Cancer: Current Therapy and Guidelines from the Children's Cancer Group 1997, Johns Hopkins University Press, Baltimore. 2nd ed. A.R. Ablin (Ed.).
444. Kong SJ, de Vathaire F, Chompret A, Shumsaldim A, Grimaud E, Raguin MA, Oberlin O, Borugleres L, Feunteun Eschwege J, Lemerle J, Bonaiti-Peuie C Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet 1997, 350:91-95.
445. Lipshultz SE, Colon SD Cardiovascular trials in long term survivors of childhood cancer. J Clin Oncol 2004, 22:769-773.
446. Moshang T Use of growth hormone in children surviving cancer. Med Pediatr Oncol 1998, 31:170-172.
447. Pratt CB, Meyer WH, Luo X, Cain AM, Kaste SC, Pappo AS, Rao BN, Flemming ID, Jenkins JJ Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer 1997, 80:960-965.
448. Pui CH, Cheng C, Leung W, Rai SN, Rivera GK, Sandlund JJ, Ribiero RC, Rolling MV, Kien LE, Evans WE, Hudson MH Extended follow-up of long term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 2003, 349(7):640-649.
449. Robinson LL, Bhatia S Late effects among survivors of leukemia and lymphoma during childhood and adolescence. Br J Haematol 2003, 122:345-359.
450. Ross L, Johansen C, Dalton SO, Mellemkjaer L, Thomassen LH, Martensen PB, Olsen JH Psychiatric hospitalization among survivors of cancer in chilhood and adolescence. N Engl J Med 2003, 349(7):650-657.
451. Sandoval C, Pui CH, Bowman LC, Heaton D, Hurwitz C, Raimondi SL, Behm FG, Head DR Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors and irradiation. J Clin Oncol 1993, 11:1039-1045.
452. Schwartz CL, Hobbie WL, Constine LS, Ruccione KS Survivors of Childhood Cancer: Assessment and Management 1994, Mosby, St. Louis.
453. Smith S, Schiffman G, Karayalcin G, Bonagura V Immune deficiency in long-term survivors of acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster therapy. J Pediatr 1995, 127:68-75.
454. Walter AW, Hancock ML, Pui CH, Hudson MM, Ochs JS, Rivera GK, Pratt CB, Bayett JM, Kuh LE Secondary brain tumors in children treated for acute lymphoblastic leukemia at St. Jude Children's Research Hospital. J Clin Oncol 1998, 16:3761.